Early Detection Research Network

MIF

Aliases:
This biomarker is also known as:
  • GIF,
  • phenylpyruvate tautomerase,
  • GLIF,
  • MIF,
  • Glycosylation-inhibiting factor,
  • MMIF,
  • macrophage migration inhibitory factor (glycosylation-inhibiting factor),
  • L-dopachrome isomerase,
  • macrophage migration inhibitory factor,
  • L-dopachrome tautomerase,

Description…

MIF, a lymphokine involved in cell-mediated immunity, immunoregulation, and inflammation, plays a role in the regulation of macrophage function in host defense through the suppression of anti-inflammatory effects of glucocorticoids. This lymphokine and the JAB1 protein form a complex in the cytosol near the peripheral plasma membrane, which may indicate an additional role in integrin signaling pathways. MIF is also closely related to tumorigenesis.

Datasets

There are no datasets associated with this biomarker.

Attributes
QA State: Curated
Type: Protein
HGNC Name: MIF

The following organs have data associated with this biomarker…

Attributes

Phase: One
QA State: Under Review

Overview

Reports have demonstrated that MIF expression is increased in premalignant, malignant, and metastatic tumors and a potential therapeutic target in NSCLC.

Performance Comment

MIF belongs to a 9-member panel that provides a quantitative measure of the probability of having lung cancer that goes beyond the histological evaluation of preinvasive lesions. The identified members of the panel are TMSB4X (Thymosin beta-4), Ubiquitin, des-ubiquitin, ACBP, CSTA, Cytochrome C, and MIF.

Attributes

Phase: Three
QA State: Curated

Overview

MIF RNAi significantly inhibited MIF expression in HO-8910 and OVCAR-3 cells and decreased cell proliferation of the two cells (P<0.05). Positive expression of MIF protein was detected in 53.5% of ovarian carcinoma tissues and was positively correlated to clinical stages of patients (P<0.01).

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. MIF alone was not a strong predictor.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.